<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673309</url>
  </required_header>
  <id_info>
    <org_study_id>00-454</org_study_id>
    <secondary_id>P50GM060338</secondary_id>
    <secondary_id>R01GM056687</secondary_id>
    <secondary_id>SHC #8660</secondary_id>
    <nct_id>NCT00673309</nct_id>
  </id_info>
  <brief_title>Assessment of Mechanisms of Improved Wound Healing</brief_title>
  <official_title>Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find ways to improve wound healing and decrease the negative
      effects of trauma from burn injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves research and the investigators hope to learn the following: how or what
      effect one or more anabolic (&quot;tissue building&quot;) agents have on muscle metabolism, wound
      healing, and immune function after severe burn. The agents include the following: growth
      hormone, insulin-like growth factor-1 in combination with its binding proteins, insulin,
      Beta-adrenergic blockers, Alpha Adrenergic Agonist, anabolic steroids such as testosterone,
      Oxandrolone and nandrolone, ketoconazole and its derivatives, dehydroepiandrosterone,
      fenofibrate, diet or the application of skin substitute.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease hypermetabolism as measured by stable isotope infusion study</measure>
    <time_frame>Admission to burn unit to 95% wound healing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved rate of wound healing</measure>
    <time_frame>Admission to burn unit to 95% wound healing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of morbidity and mortality</measure>
    <time_frame>Admission to burn unit to discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of sepsis</measure>
    <time_frame>Admission to burn unit to 95% wound healing</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">644</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Hormone 0.05 to 0.2 mg/kg q day SQ until 95% wound healing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGF-1 (or IGF-1/IGFBP-3) administration daily until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin IV administered continuously to maintain serum glucose between 80-110 throughout hospitalization until wounds are 95% healed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxandrolone (or other Anabolic steroid-nandrolone or testosterone) administered daily until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol (or other Beta adrenergic blockers-metoprolol) to be given IV or PO to decrease HR and BP throughout hospitalization until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clonidine (Alpha Adrenergic Agonist) to be given daily to decrease HR and BP and anxiety</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoconazole (or other glucocorticoid blockers- itraconazole, fluconazole) administered PO every 12 hours throughout hospitalization until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fenofibrate administered daily until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone administered daily throughout hospitalization to 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Byetta (or other Glucagon like peptide drug-GLP, GLP-1, Exenatide) will be administered SQ daily throughout hospitalization until 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. Sterile water will be administered daily throughout hospitalization to 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin PO administered daily throughout hospitalization to 95% wound healing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA-S, Dehydroepiandrosterone-sulfate administered daily until 95% wound healing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of blood and tissues</intervention_name>
    <description>Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <arm_group_label>11</arm_group_label>
    <arm_group_label>12</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stable Isotope Infusion study</intervention_name>
    <description>1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <arm_group_label>11</arm_group_label>
    <arm_group_label>12</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiology testing: DEXA, K+ counter, ultrasound, MRI</intervention_name>
    <description>Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <arm_group_label>11</arm_group_label>
    <arm_group_label>12</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGF-1</intervention_name>
    <description>Administration of randomized drug daily throughout hospitalization to 95% wound healing</description>
    <arm_group_label>2</arm_group_label>
    <other_name>IGF-1/IGFBP-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin IV administered continuously to maintain serum glucose between 80-110 throughout hospitalization until wounds are 95% healed.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Regular Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxandrolone</intervention_name>
    <description>Oxandrolone given daily throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>testosterone</other_name>
    <other_name>nandrolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol to be given daily to decrease HR and BP throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>metroprolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Clonidine administered daily throughout hospitalization until 95% wound healing to decrease HR, BP, and anxiety.</description>
    <arm_group_label>6</arm_group_label>
    <other_name>Catapres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole administered PO every 12 hours throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>7</arm_group_label>
    <other_name>itraconazole</other_name>
    <other_name>fluconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone-sulfate</intervention_name>
    <description>The hormone Dehydroepiandrosterone-sulfate will be given daily until 95% wound healing.</description>
    <arm_group_label>13</arm_group_label>
    <other_name>DHEA-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Fenofibrate administered daily until 95% wound healing.</description>
    <arm_group_label>8</arm_group_label>
    <other_name>Tricor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin to be administered daily throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>9</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Byetta</intervention_name>
    <description>Byetta administered daily throughout hospitalization until 95% wound healing.</description>
    <arm_group_label>11</arm_group_label>
    <other_name>GLP</other_name>
    <other_name>GLP-1</other_name>
    <other_name>Exenatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>Recombinant Human Growth hormone to be administered daily until 95% wound healing.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>GH</other_name>
    <other_name>rhGH</other_name>
    <other_name>recombinant human Growth Hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone administered daily throughout hospitalization until 95% wound healing</description>
    <arm_group_label>10</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is between 0 and 90 years of age

          -  Patient 18 years and older consents to participate in study protocol. If patient is
             not able to consent, consent will be obtained from closest family member or legal
             guardian. Parental permission will be obtained for patients less than 18 years of age.
             Assent will be obtained from children 7-17 years of age if child is
             physically/mentally able to do so.

          -  greater than 30% TBSA burn requiring at least 1 operation with donor sites for skin
             grafting

        Exclusion Criteria:

          -  Known history of AIDS, AIDS-related complex, Human Immunodeficiency Virus

          -  History of cancer within 5 years

          -  Tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases,
             autoimmune diseases

          -  Chronic glucocorticoid or non-steroidal anti-inflammatory drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N. Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>burns</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Oxandrolone</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

